To further elucidate the efficacy of SIM administration against lipid metabolism disorders, hepatic mRNA expression levels of BESP, CYP7A1, ACAT2, SREBP-1C, CD36, and HMGCR are investigated. This evidence concerns the gene ACAT2 and Disorder of lipid metabolism.